Translational route and clinical experience in adoptive immunoter | 59590
International Journal of Biomedical Data Mining

International Journal of Biomedical Data Mining
Open Access

ISSN: 2090-4924

Translational route and clinical experience in adoptive immunoterapy by Oncocit; 3rd generation of dendritic cell vaccine

2nd International conference on Immunity and Immunochemistry

August 09, 2021 | WEBINAR

Ramon Ernesto Gutierrez Sandoval

Oncocit, USA

Keynote: Int J Biomed Data Min

Abstract :

Introduction: Immunotherapy its positioned as the new “fifth essence” of cancer treatment providing new therapeutic responses not seen so far. There are different protocols and mechanisms of action, highlighting the 2018 Nobel Prize for chekpoint inhibitors, T-car therapy for hematological malignancies and the dendritic cell vaccine for solid tumor whose biotechnology has the nobel of 2011 and FDA approval since 2010. Conclusion: Dendritic cell immunotherapy is developed essentially from a sample of the patient’s blood and a sample of his cancer biopsy to be treated. It is a treatment feasible, validable, perfectible, safe application and reasonable effectiveness. The 3rd generation vaccine is 15 to 20 times more effective than the 1st generation, because includes molecular signals 1, 2 and 3 which ensures a type 1 immune polarization of CD4 + T cells and efficient cytotoxic responses of cytotoxic CD8 + T cells (CTL), that ensures anti-tumor programming and prevents immune weakening or immunosuppression. This protocol requires molecular profiles of cytokines, that we have as “ready-to-use” packaging (terkit, bitex) thus facilitating the implementation in a greater number of laboratories, with lower final cost of treatment and greater coverage to patients. The greater complementary effectiveness of dendritic cell immunotherapy includes its use close to cancer diagnosis, previous or simultaneous tumor mass reduction with conventional therapies (surgery, chemo and radiotherapy) programming with optimal stimulation signals, enriched pulsation, use of exosomes and “supernatant”, intensive protocol options, reinforcements cell validation, controls supported by flow cytometry and specialized logistics. Keywords: dendritic cell, vaccine, cancer, immunotherapy, third, generation, terkit, bitex, oncocit, recell

Biography :

Ramón Gutierrez is MD by U. de Concepción and pathologist from University of Chile. In USA he holds an MSL© Medical Science Liaison degree from UC Berkeley. In Spain he obtained a Master’s Degree in Clinical Oncology from the University of the Basque Country and a Master’s Degree in Molecular Oncology from the Center for Biosanitary Studies (CEB) and Rey Juan Carlos University program. He is founder of Laboratorio Bioclas ( and RECELL Cancer Center in Chile ( Biogenica Consortium in Panama (biogénica. org) and Oncocit LLC in USA (oncocit. com) and he is based in medical city of Lake Nona, in Orlando, Fl. He has obtained competitive funds from the Chilean government for his cancer research and has specialized in clinical treatment of adoptive immunotherapy for cancer through 3rd generation dendritic cell vaccines, with more than 1500 annual applications for patients in 24 countries of Latin America.